Several distinct genetic abnormalities, including somatic mutations in genes such as MYD88, CD79B, and MYC, have been identified in DLBCL, and single or combined mutations have been shown to have prognostic value in DLBCL subtypes [22–24]. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.